Summary & Overview
HCPCS J9015: Aldesleukin Injection, Single-Use Vial
HCPCS Level II code J9015 denotes the single-use vial injection of aldesleukin, a recombinant interleukin-2 biologic used in certain oncology and immunotherapy settings. Nationally, this code matters because it captures administration of a high-cost injectable biologic that has implications for facility billing, payer coverage policies, and site-of-service cost differentials. Payers commonly applying coverage rules to this code include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find a concise overview of what J9015 represents, how it is used across typical sites of care (hospital outpatient departments, physician offices, and infusion centers), and which payers are relevant for coverage considerations. The publication provides benchmarks where available, summarizes common billing and coding themes tied to injectable biologics, and highlights recent policy trends affecting drug administration codes. It also outlines clinical context for aldesleukin administration and what information billing professionals and policy analysts should track when evaluating utilization and reimbursement for J9015. Data not provided in the input (such as associated taxonomies, ICD-10 diagnoses, and related codes) are noted as unavailable.
Billing Code Overview
HCPCS Level II code J9015 represents the injection of aldesleukin, billed per single-use vial. This code covers administration of the recombinant interleukin-2 product formulated for subcutaneous or intravenous injection for clinical indications where aldesleukin is indicated.
Service Type: Drug administration / injectable biologic
Typical Site of Service: Hospital outpatient department, physician office, or infusion center
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 58-year-old patient with metastatic renal cell carcinoma presents to an outpatient oncology infusion suite for administration of high-dose interleukin-2 (aldesleukin) using a single-use vial. The oncology nurse verifies orders, confirms baseline vital signs and organ function labs, and obtains informed consent for systemic therapy. The medication J9015 is prepared in pharmacy under aseptic technique and transported to the infusion area. The patient is monitored continuously during and after the injection for expected cytokine-mediated adverse effects (fever, hypotension, capillary leak) and for signs of infusion-related reactions. Documentation includes indication, lot number, vial count, route, dose per vial, start and stop times, and any modifier-specific events such as partial vial wastage or discontinued administration. Typical sites of service include hospital inpatient oncology units for high-dose protocols and outpatient hospital or freestanding infusion centers for lower-intensity or single-vial administrations.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug discarded/not administered to any patient | Use when part of a single-use vial is wasted and documentation supports discarded amount |